Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 15 от 222

Recruiting Phase 2

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

Drug Susceptible Pulmonary Tuberculosis

The purpose of this study is to determine if nicotinamide in combination with bedaquiline, pretomanid, and linezolid, is safe and effective in treating drug-susceptible pulmonary tuberculosis.

Начало: 13.04.2026 Край: 14.06.2027 Възраст: 18–65 г.

South Africa Gates Medical Research Institute NCT07517445

Recruiting Phase 2

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

Advanced Solid Tumour

An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.

Начало: 13.04.2026 Край: 30.05.2028 Възраст: от 18 г.

China Nanjing Leads Biolabs Co.,Ltd NCT07390383

Recruiting Phase 1

A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants

Overweight , Obesity

This study is a single-dose, open-label, parallel design phase I clinical study to evaluate the PK characteristics and safety of single subcutaneous injection of ZT002 Injection in participants with different degrees of renal insufficiency and matched participants with normal renal function.

Начало: 13.04.2026 Край: 19.03.2027 Възраст: 18–75 г.

China Beijing QL Biopharmaceutical Co.,Ltd NCT07443059

Recruiting Phase 2

An Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism

Hypoparathyroidism

XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.

Начало: 13.04.2026 Край: 30.07.2030 Възраст: 18–90 г.

China Peking Union Medical College Hospital NCT07540286

Recruiting Phase 4

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Metastatic Melanoma Advanced Melanoma

The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.

Начало: 13.04.2026 Край: 01.05.2031 Възраст: от 18 г.

United States NYU Langone Health NCT07504796

Recruiting

HEalthCAre Workers' Health: a Transversal Evaluation

Occupational Health

The research focuses on assessing the overall health of residents at the Cochin Port Royal hospital Group. * physical health * Mental health: detection of signs of anxiety, depression, eating disorders, substance abuse, etc. * Sexual health * Quality of medical care (dental, gynecological) * Knowledge of risk prevention, particularly infectious risks, in the workplace.

Начало: 13.04.2026 Край: 01.06.2027 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT06588621

Recruiting Phase 2

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma

This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).

Начало: 13.04.2026 Край: 01.04.2028 Възраст: 18–75 г.

China Shanghai Junshi Bioscience Co., Ltd. NCT07484724

Recruiting

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

This is a single-arm, open-label, phase II study to evaluate the efficacy and safety of the combination of the antibodies iparomlimab and tuvonralimab, administered with or without chemotherapy, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have progressed after receiving at least one line of systemic therapy. The study includes a safety run-in phase with approximately three patients, which may be expanded to six if a dose-limiting toxicity is observed. Patients are then assigned to either combination antibody monotherapy or combination antibody plus chemotherapy, based on PD-L1 combined positive score (CPS), symptom burden, disease characteristics and patient preference. Monotherapy involves iparomlimab and tuvonralimab (5 mg/kg on day 1, every 3 weeks). Combination therapy involves the same antibody regimen plus up to six cycles of platinum (carboplatin at an area under the curve (AUC) of 5 or cisplatin at 75 mg/m²) plus docetaxel (75 mg/m²) or paclitaxel (135-175 mg/m²), followed by antibody monotherapy maintenance. The primary objective is to assess the objective response rate (ORR) according to RECIST 1.1. The secondary objectives are to evaluate the disease control rate (DCR), the 6-month progression-free survival (PFS) rate, the 6-month overall survival (OS) rate and the safety profile. Exploratory objectives include the association of tumour biomarkers (PD-L1 expression and tumour mutation burden) with efficacy.

Начало: 13.04.2026 Край: 31.12.2028 Възраст: 18–75 г.

China The Second Affiliated Hospital of Hainan Medical Univer NCT07546383

Recruiting Phase 1

To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers

Healthy

This clinical study is a phase 1, randomized, double-blind, placebo-controlled, dose escalation clinical trial to evaluate the safety, pharmacokinetic and pharmacodynamics of JW0061 following topical application in Korean and Caucasians healthy adults.

Начало: 13.04.2026 Край: 30.04.2027 Възраст: 19–55 г.

South Korea JW Pharmaceutical NCT07514780

Recruiting

Safety and Effectiveness of Bambini Kids Robot-Assisted Gait Training (RAGT) in Children With Cerebral Palsy

Cerebral Palsy (CP)

Cerebral palsy (CP) is a common cause of gait impairment in children, leading to limitations in mobility and daily activities. Although conventional physical therapy is widely used, it has limitations in delivering consistent and intensive training. Robot-assisted gait training (RAGT) has emerged as a promising approach to provide repetitive, high-intensity, and task-specific training, with potential benefits in gait function and motor performance. The Bambini Kids exoskeleton is a pediatric robotic device designed to assist lower-limb movements, including hip, knee, and ankle joints, to facilitate more natural gait patterns. This study aims to evaluate the safety and clinical performance of Bambini Kids in children with cerebral palsy and to generate clinical evidence to support its use in real-world rehabilitation settings.

Начало: 13.04.2026 Край: 31.12.2026 Възраст: 2–10 г.

South Korea COSMO ROBOTICS CO., Ltd NCT07539389

Recruiting

Analysis of the Reliability and Validity of Laser Speckle Contrast Imaging

Gingival Vascularization Oral Soft Tissue Wound Healing Laser Speckle Contrast Imaging Periodontal Wound Healing

This study is designed to validate laser speckle contrast imaging (LSCI) as a non-invasive method for measuring superficial gingival blood perfusion. Accurate assessment of vascularization is essential for understanding periodontal and peri-implant wound healing, yet current clinical methods are limited by subjective interpretation and low reproducibility. Repeated LSCI measurements will be performed in healthy gingival tissues and in tissues undergoing different mucogingival healing patterns, including primary and secondary intention healing. The study will also evaluate factors that may influence perfusion readings, such as angulation, retractors, mirror use, temperature, and heart rate. The primary objective is to determine the reproducibility of LSCI measurements and to support its use as a reliable tool for monitoring oral soft-tissue vascularization and healing.

Начало: 13.04.2026 Край: 20.05.2026 Възраст: от 18 г.

Spain Universidad Complutense de Madrid NCT07527351

Recruiting

Tumor-Lymph Node Mapping

Pediatric Solid Tumors Rhabdomyosarcoma Sarcoma Germ Cell Tumor

The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection/sampling. This trial is a single-site cross-sectional study. The injection of ICG directly into lymphatics draining the primary tumor will take place at the time of operation after the patient is under anesthesia.

Начало: 13.04.2026 Край: 30.07.2028 Възраст: 1–17 г.

United States University of Rochester NCT07054944

Recruiting

Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.

Head & Neck Squamous Cell Carcinoma

This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.

Начало: 13.04.2026 Край: 13.06.2029 Възраст: от 18 г.

France University Hospital, Brest NCT07417605

Recruiting

Invasive Home Ventilation in Denmark

Neuromuscular Diseases (NMD) ALS (Amyotrophic Lateral Sclerosis) Spinal Cord Injuries (SCI) Duchenne Muscular Dystrophy (DMD) +4

The aim of this study is to describe national trends over the past 10 years in patients receiving invasive home mechanical ventilation (HMV) in Denmark. This includes indications for invasive HMV, diagnostic groups, and one-year mortality.

Начало: 13.04.2026 Край: 01.09.2028

Denmark Rigshospitalet, Denmark NCT07467187

Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Stage IIB-III NSCLC Sleeve Lobectomy Robotic Surgery Neoadjuvant Chemoimmunotherapy

The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are: What is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy? What factors are associated with unsuccessful surgery? How do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures? In this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.

Начало: 13.04.2026 Край: 30.05.2027

China, France, Italy Shanghai Chest Hospital NCT07541521

Recruiting Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Small Cell Lung Cancer (SCLC) Extensive-stage Small Cell Lung Cancer (ES-SCLC)

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Начало: 13.04.2026 Край: 30.07.2029 Възраст: от 18 г. Treatment

Argentina, Australia, Austria +40 Boehringer Ingelheim NCT07472517

Recruiting

The Effectiveness and Acceptability of Formal Versus Informal Mindful Self-Compassion for Adolescents

Coping

The goal of this clinical trial is to learn if two types of mindful self-compassion programs work to improve coping in adolescents. The investigators will also learn about adolescents' liking of, and the other potential mental health and academic benefits of, these programs. The main questions this clinical trial aims to answer are: * Do two types of mindful self-compassion programs improve coping in adolescents? * Do two types of mindful self-compassion programs improve mental health (e.g., stress, anxiety, depression) and academic outcomes (e.g., academic engagement) in adolescents? * How satisfactory are two types of mindful self-compassion programs for adolescents? To do this, the investigators will compare adolescents who complete two types of mindful self-compassion programs to adolescents in a "waitlist control" condition (who complete no study tasks during the program period, but will have the opportunity to complete the program at the end of the study). Participants will: * Complete a brief phone interview to confirm their eligibility (15 min) * Complete an online survey including questions about coping, mental health, and academic engagement (30 min) * Complete a live, online, four-week-long mindful self-compassion program OR no study tasks during this four-week period (if randomly assigned to a waitlist condition) * Complete an online survey 1 week after the 4-week period, including questions about coping, mental health, and academic engagement, as well as their liking of the program they completed (if applicable) * Complete an online survey 1 month after the 4-week period, including questions about coping, mental health, and academic engagement * (Waitlist condition only) Have the opportunity to complete one of the two mindful self-compassion programs after the study had ended

Начало: 13.04.2026 Край: 30.04.2027 Възраст: 14–19 г.

United States Cambridge Health Alliance NCT07513220

Recruiting

AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

The precise treatment of primary hepatocellular carcinoma (HCC) highly depends on accurate disease staging (CNLC, TNM, BCLC) and scientific treatment decision-making, which necessitate the integration of both imaging and clinical baseline data. This study prospectively recruits HCC patients and clinical physicians across different hospital tiers to evaluate the clinical value of a self-developed artificial intelligence (AI) model in assisting multi-dimensional comprehensive assessment and treatment decision-making. Utilizing a Multi-Rater Multi-Case (MRMC) crossover balanced design, the study compares the accuracy of clinical evaluations performed by physicians under "unassisted (without AI)" versus "AI-assisted" conditions. A key focus is to explore whether AI can significantly enhance the comprehensive assessment capabilities of physicians in primary/secondary care hospitals, thereby prospectively reducing diagnostic and therapeutic heterogeneity across different institutional levels.

Начало: 13.04.2026 Край: 20.05.2026 Възраст: от 18 г.

China Beijing Tsinghua Chang Gung Hospital NCT07538882

Recruiting Phase 2

A Phase 2, multicenter, open label, non-randomized study to evaluate the efficacy and safety of extended dosing of belantamab mafodotin in different combinations with standard of care regimens in participants with relapsed-refractory multiple myeloma (DREAMM-15)

Relapsed or Refractory Multiple Myeloma

Trial status: Authorised • CRR, defined as the percentage of participants with a confirmed CR or better. • MRD negativity rate, defined as the percentage of participants who achieve MRD negative status at least once during the time of confirmed CR or better response as per IMWG. • DoR, defined as the time from first documented evidence of PR or better until PD or death due to any cause., • Incidence and severity of AEs and SAEs; • Incidence of AEs leading to dose modifications or study intervention discontinuation; • Incidence and severity of ocular findings on ophthalmic exam (changes in VA and cornea findings)., OSDI, PRO-CTCAE (ocular), PROSIM-Q, and CTCAEs (eye disorders – other) concordance with KVA ORR, defined as the percentage of participants with a confirmed PR or better (i.e., PR, VGPR, CR, sCR).

Начало: 13.04.2026 Възраст: от 18 г.

France, Germany, Greece +2 Glaxosmithkline Research & Development Limited 2025-523117-28-00

Recruiting Phase 2

Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease

Interstitial Lung Disease (ILD)

The purpose of this study is to assess the effect of L-menthol on breathlessness and exercise capacity in patients with Interstitial lung disease (ILD).

Начало: 13.04.2026 Край: 01.05.2027 Възраст: от 18 г.

Sweden Region Skane NCT07398287

1 … 13 14 15 16 17 … 222